Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective

TY - JOUR

T1 - Future of Rare Diseases Research 2017–2027

T2 - An IRDiRC Perspective

AU - Austin, Christopher P.

AU - Cutillo, Christine M.

AU - Lau, Lilian P.L.

AU - Jonker, Anneliene H.

AU - Rath, Ana

AU - Julkowska, Daria

AU - Thomson, David

AU - Terry, Sharon F.

AU - de Montleau, Béatrice

AU - Ardigò, Diego

AU - Hivert, Virginie

AU - Boycott, Kym M.

AU - Baynam, Gareth

AU - Kaufmann, Petra

AU - Taruscio, Domenica

AU - Lochmüller, Hanns

AU - Suematsu, Makoto

AU - Incerti, Carlo

AU - Draghia-Akli, Ruxandra

AU - Norstedt, Irene

AU - Wang, Lu

AU - Dawkins, Hugh J.S.

AU - on behalf of the International Rare Diseases Research Consortium (IRDiRC)

N1 - Funding Information: Acknowledgments. The authors thank the present representatives of the IRDiRC Consortium Assembly, present members of the IRDiRC Scientific Committees, and Scientific Secretariat for their contribution to this collaborative effort (see Supplementary Information). The authors would also like to thank all participants of the 3rd IRDiRC Conference in Paris for their feedback on the vision and goals for the next decade. IRDiRC Scientific Secretariat is supported by the European Commission FP7 contract, “SUPPORT-IRDiRC” (No 305207) and HL is supported by the European Commission FP7 contract, “RD-Connect” (No 305444). CPA has contributed to this work in his capacity as Chair of the IRDiRC Consortium Assembly, not in his role as director of the National Center for Advancing Translational Sciences. Funding Information: The authors thank the present representatives of the IRDiRC Consortium Assembly, present members of the IRDiRC Scientific Committees, and Scientific Secretariat for their contribution to this collaborative effort (see Supplementary Information). The authors would also like to thank all participants of the 3rd IRDiRC Conference in Paris for their feedback on the vision and goals for the next decade. IRDiRC Scientific Secretariat is supported by the European Commission FP7 contract, ?SUPPORT-IRDiRC? (No 305207) and HL is supported by the European Commission FP7 contract, ?RD-Connect? (No 305444). CPA has contributed to this work in his capacity as Chair of the IRDiRC Consortium Assembly, not in his role as director of the National Center for Advancing Translational Sciences. The views expressed in this publication are the sole responsibility of the authors and do not necessarily reflect the views of their affiliated organizations. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of the information. CPA contributed in his capacity as Chair of the IRDiRC Consortium Assembly, not in his role as the Director of the National Center for Advancing Translational Sciences.

PY - 2018/1

Y1 - 2018/1

UR - https://www.scopus.com/pages/publications/85040288351

U2 - 10.1111/cts.12500

DO - 10.1111/cts.12500

M3 - Review article

C2 - 28796445

AN - SCOPUS:85040288351

SN - 1752-8054

VL - 11

SP - 21

EP - 27

JO - Clinical and Translational Science

JF - Clinical and Translational Science

IS - 1

ER -